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H E A L T H  A N D  M E D I C I N E
Covalent chemistry on nanostructured substrates 
enables noninvasive quantification of gene 
rearrangements in circulating tumor cells
Jiantong Dong1,2, Yu Jen Jan1,3, Ju Cheng1, Ryan Y. Zhang1, Meng Meng1,4, Matthew Smalley1, 
Pin-Jung Chen1,3, Xinghong Tang1, Patrick Tseng1, Lirong Bao1, Tzu-Yang Huang5, 
Dongjing Zhou6, Yupin Liu6, Xiaoshu Chai6, Haibo Zhang6, Anqi Zhou1, Vatche G. Agopian7, 
Edwin M. Posadas3, Jing-Jong Shyue8, Steven J. Jonas9, Paul S. Weiss10, Mengyuan Li2*, 
Guangjuan Zheng6*, Hsiao-hua Yu5*, Meiping Zhao2*, Hsian-Rong Tseng1*, Yazhen Zhu1*
Well-preserved mRNA in circulating tumor cells (CTCs) offers an ideal material for conducting molecular profiling 
of tumors, thereby providing a noninvasive diagnostic solution for guiding treatment intervention and monitoring 
disease progression. However, it is technically challenging to purify CTCs while retaining high-quality mRNA.
Here, we demonstrate a covalent chemistry–based nanostructured silicon substrate (“Click Chip”) for CTC purification 
that leverages bioorthogonal ligation–mediated CTC capture and disulfide cleavage–driven CTC release. This 
platform is ideal for CTC mRNA assays because of its efficient, specific, and rapid purification of pooled CTCs, 
enabling downstream molecular quantification using reverse transcription Droplet Digital polymerase chain reaction. 
Rearrangements of ALK/ROS1 were quantified using CTC mRNA and matched with those identified in biopsy speci-
mens from 12 patients with late-stage non–small cell lung cancer. Moreover, CTC counts and copy numbers of 
ALK/ROS1 rearrangements could be used together for evaluating treatment responses and disease progression.
INTRODUCTION
The use of circulating tumor cells (CTCs) (1) as a surrogate tumor 
source for molecular profiling of disease offers a potential non-
invasive diagnostic solution for understanding underlying tumor biology, 
guiding treatment interventions, and monitoring disease progression. 
Unlike circulating tumor DNA or RNA (2), which are highly frag-
mented and compounded by substantial background, CTCs house 
intact genomic DNA and RNA, providing more genetic informa-
tion about the tumors from which they originate. Recently, research 
focus has shifted away from the capture and enumeration of CTCs, 
and instead, toward approaches that enable in-depth mRNA profiling 
of both single and pooled CTCs (3–9). For example, transcriptome 
profiling was performed with full-length mRNA sequencing at the 
single CTC level with both prostate and melanoma CTCs, providing 
a glimpse into the in-depth biology of the diseases (4, 5). Compared 
with single-CTC mRNA assays, which are limited to relatively low 
quantities of RNA, enriched pools of CTCs that are coupled with 
sensitive downstream molecular profiling show greater translational 
potential in the clinic. So far, pooled CTCs have been used to detect 
hepatocellular carcinoma (HCC) (6), predict treatment responses 
and early dissemination in prostate cancer (7), and monitor early 
responses to immune checkpoint therapy in melanoma (8). We have 
also exploited pooled-CTC mRNA profiling for early detection of 
metastatic prostate cancer (9). However, to explore the diagnostic 
applications of pooled-CTC mRNA, technical challenges, including 
the low purity of enriched CTCs [from contamination by nonspe-
cific binding of white blood cells (WBCs)] and the short lifetime of 
mRNA, must be addressed. Therefore, it is critical to develop a new 
platform that is optimized for pooled-CTC mRNA assays. Such a 
platform must be capable of (i) capturing and releasing pooled CTCs 
with minimal background WBC contamination and (ii) quickly and 
gently recovering pooled CTCs with well-preserved mRNA so that 
it can be seamlessly coupled with sensitive and reliable downstream 
molecular analysis.
In addition to CTC-based mRNA profiling, well-preserved mRNA 
in CTCs enables the detection and quantification of oncogenic gene 
rearrangements, which represent an unmet clinical need and remain 
unexploited by current CTC mRNA analyses. The presence of ana-
plastic lymphoma kinase (ALK) and ROS1 rearrangements define a 
subgroup of patients with non–small cell lung cancer (NSCLC) who 
are highly responsive to ALK/ROS1 tyrosine kinase inhibitors (TKIs), 
e.g., crizotinib (10, 11). Oncologists are increasingly receptive to 
noninvasive diagnostic solutions that enable both initial detection 
and continuous monitoring of NSCLC progression (12). Given that 
(i) mRNA has a relatively limited lifetime and (ii) there are multiple 
forms of rearranged transcripts (13–15), detection and precise 
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quantification of ALK/ROS1 rearrangements in the blood of pa-
tients with NSCLC have proven challenging, further underscoring 
the need for an optimized CTC platform with the capacity to recover 
high-quality intact mRNA quickly for gene rearrangement analysis. 
Moreover, among the various downstream mRNA assays, reverse 
transcription Droplet Digital polymerase chain reaction (PCR) 
(RT-ddPCR) (16) is ideal for detecting gene rearrangements in CTCs. 
On the basis of a unique water-oil emulsion technology, RT-ddPCR 
offers a streamlined workflow for quantifying small amounts of 
CTC mRNA with single-molecule precision. Furthermore, RT-ddPCR 
can identify the partners of potential gene rearrangements through 
its PCR primer and reporter design.
In our previous studies, inspired by nanoscale features present in 
the tissue microenvironment (e.g., extracellular matrix and cell sur-
face components), we pioneered (17, 18) the design and application 
of “NanoVelcro” cell-affinity substrates, in which capture agents 
(e.g., antibodies) can be grafted onto silicon nanowire substrates 
(SiNWS) (19) to capture cells of interest [e.g., CTCs and circulating 
fetal nucleated cells (20)]. The Velcro-like topographic interactions 
(17, 19) between the nanostructured substrates and nanoscale cellular 
surface components (i.e., microvilli) confer enhanced cell capture 
performance to the devices.
In this study, on the basis of our previous experience (9) isolating 
pooled CTCs, we exploited a new covalent chemistry–based CTC 
capture/release platform to address the unmet clinical need of 
quantifying gene rearrangements in CTCs. This platform was developed 
by integrating bioorthogonal ligation–mediated (21) CTC capture with 
disulfide cleavage–driven CTC release on nanostructured substrates to 
enable more efficient purification of pooled CTCs with well-preserved 
mRNA and less WBC contamination (Fig. 1). We used bioorthogonal 
click chemistry, i.e., inverse electron-demand Diels-Alder cycloaddi-
tion (22) between tetrazine (Tz) and trans- cyclooctene (TCO) with a 
rate constant (23) of 104 M−1 s−1, to mediate CTC capture and enu-
meration in SiNWS-embedded microfluidic devices and thus refer 
to them as “Click Chips.” Anti–epithelial cell adhesion molecule 
(EpCAM) has been widely used in many CTC enrichment platforms 
such as the only U.S. Food and Drug Administration– approved 
CellSearch (24). In contrast to previous anti-EpCAM–mediated 
CTC immobilization methods, a pair of highly reactive click chemistry 
motifs, i.e., Tz and TCO, were grafted onto cell capture substrates 
(via surface modification) and CTCs (via TCO–anti-EpCAM 
conjugation), respectively. The ligation between Tz-grafted SiNWS 
and TCO-grafted CTCs is facile, specific, irreversible, and insensitive 
to biomolecules, water, and oxygen (22), leading to specific, rapid, 
and irreversible immobilization of the CTCs with improved capture 
efficiency and reduced nonspecific immobilization of WBCs compared 
with that observed in previously reported anti-EpCAM–mediated 
approaches (19, 25). After CTC capture, exposure to a disulfide 
cleavage agent [i.e., 1,4-dithiothreitol (DTT)] (26) results in the prompt 
release of the CTCs from the SiNWS by cleaving the disulfide bond 
linking the Tz to the SiNWS. As WBCs are captured nonspecifically, 
they are not released by freeing Tz from the SiNWS, reducing WBC 
contamination in the released samples. In addition, mRNA stability 
is improved as a result of the (i) short CTC purification time (24 min) 
and (ii) mild processing conditions, enabling downstream mRNA 
analysis by RT-ddPCR (16). We demonstrate that Click Chips can 
be used for the detection and quantification of oncogenic gene rear-
rangements (i.e., ALK/ROS1 rearrangements) in CTCs isolated from 
patients with NSCLC, enabling serial monitoring of ALK/ROS1 
rearrangements with single-molecule precision. Leveraging this 
Fig. 1. Schematic illustrating the combined use of bioorthogonal ligation (i.e., the reaction between Tz and TCO) and disulfide cleavage–driven by DTT to 
enable capture and release of CTCs using Click Chips. The purified CTCs can then be subjected to RT-ddPCR to detect ALK or ROS1 rearrangements in NSCLC samples 
with single-molecule precision. cDNA, complementary DNA.
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capability, we correlate dynamic changes in both CTC count and 
quantity of CTC-derived ALK/ROS1 rearrangements with outcomes 
from radiographic imaging, the clinical gold standard for evaluating 
treatment responses of solid tumors.
RESULTS
Device fabrication and characterization
The SiNWS of Click Chips (Fig. 1) are composed of Tz-grafted silicon 
nanowires, which are fabricated via a combination of photolitho-
graphic patterning and Ag nanoparticle–templated wet etching (27). 
The resulting vertically aligned SiNWS (19) are cut into individual 
chips and then treated to tether Tz motifs onto the nanostructures. 
As illustrated in Fig. 2A, (3-mercaptopropyl)trimethoxysilane (MPS) is 
vapor-deposited onto the SiNWS. The terminal thiol groups presented 
by the silane-treated SiNWS are then reacted with ortho-pyridyl disul-
fide polyethylene glycol amine (OPSS-PEG-NH2) to incorporate a 
disulfide linker moiety terminated by an amine group. Last, a Tz-sulfo-
NHS ester is coupled to the terminal amine to produce the Tz-grafted 
SiNWS.
X-ray photoelectron spectroscopy (XPS) was used to character-
ize and confirm the stepwise modification of the SiNWS interface 
(Fig. 2, B to D, and fig. S1). Two new characteristic peaks of S 2s and 
2p electrons from the thiol groups were observed for HS-SiNWS 
(Fig. 2, B and C), suggesting that the initial silanization reaction was 
successful. After treating the HS-SiNWS with the disulfide linker 
OPSS-PEG-NH2, a new N 1s electron peak was observed (Fig. 2, B and D), 
which confirms the presence of the linkers’ terminal amine group. 
When incubating the H2N-SiNWS with a Tz-sulfo-NHS ester, the 
intensity of the N 1s peak markedly increased, which is consistent 
with the nitrogen content of the Tz motif. Further analysis of de-
convoluted x-ray photoelectron spectra at the C 1s and N 1s regions 
confirmed the bonding structure on the surface of SiNWS (see fig. S2).
In parallel, we tested and verified the preparation of Tz-grafted 
SiNWS via the bioorthogonal ligation between Tz on SiNWS and 
Cy5-labeled TCO, which was followed by disulfide cleavage using 
DTT (Fig. 2E and figs. S3 and S4). The Cy5 fluorophore was grafted 
onto the SiNWS through a TCO and Tz coupling reaction (Fig. 2F), 
leading to a strong fluorescent signal detected on treated Tz-grafted 
SiNWS (Fig. 2G and fig. S3A). In contrast, Tz-grafted flat Si sub-
strates (without nanostructures) showed weak fluorescence after 
Cy5-labeled TCO treatment (fig. S3B), demonstrating fewer Tz 
motifs and less surface area than that of SiNWS. In addition, the 
lack of fluorescence on Cy5-labeled TCO-treated NH2-SiNWS (fig. S3C) 
confirms the specificity of the bioorthogonal click chemistry. Ex-
posing the Cy5-grafted SiNWS to DTT for a series of incubation 
times induced disulfide cleavage and release of the fluorophore from 
the SiNWS, resulting in a rapid reduction in fluorescence (Fig. 2H) 
with 90% of Cy5 fluorophores detaching from the substrate within 
12 min (fig. S4). These fluorescence data both confirm the success-
ful preparation of Tz-grafted SiNWS and demonstrate the feasibility 
of CTC capture and release from the SiNWS.
CTC capture with Click Chips
A custom-designed microfluidic chip holder was used to integrate 
Tz-grafted SiNWS with an overlaid polydimethylsiloxane (PDMS) 
component consisting of a network of microchannels modified to 
induce chaotic mixing (25, 28) to form a Click Chip, as shown in 
Fig. 1. A complementary bioorthogonal motif (i.e., TCO) is cova-
lently conjugated (29) onto anti-EpCAM. The resulting TCO–anti- 
EpCAM conjugate is then grafted onto target CTCs before capture. 
The PDMS chaotic mixer is integrated to facilitate direct physical 
contact between TCO-grafted CTCs and the Tz-grafted SiNWS. To 
optimize the operating parameters of Click Chips, we prepared 
artificial CTC samples by spiking 200 EpCAM-positive NSCLC 
cells into freshly purified human WBCs (5 × 106 cells ml−1) in a 
standard RPMI 1640 culture medium (200 l). For convenience and 
precision during cell imaging and counting, these NSCLC cells were 
prestained with a DiO green fluorescent dye before spiking, while 
the WBCs were prestained with a DiD red fluorescent dye. We ini-
tially used a NSCLC cell line with a representative ROS1 rearrange-
ment, i.e., HCC78 (SLC34A2-ROS1 rearrangement) to test and 
optimize the performance of the CTC capture and release (Fig. 3A). 
Before conducting CTC capture studies, the TCO–anti-EpCAM 
was incubated with the artificial NSCLC samples for 30 min at room 
temperature. After washing away excess antibody, the TCO-grafted 
model CTC samples were run through Click Chips. The SiNWS- 
immobilized cells or released/purified cell mixtures were then stained 
with 4′,6-diamidino-2-phenylindole (DAPI) and counted using a 
fluorescence microscope (Nikon 90i).
Figure 3C summarizes the CTC capture efficiencies and specific-
ities observed for both bioorthogonal ligation–mediated CTC cap-
ture (Click Chips, Fig. 3A) and conventional anti-EpCAM–mediated 
CTC capture (NanoVelcro assays, Fig. 3B) (25) using flow rates of 
1.0 ml hour−1. High CTC capture efficiencies (94 ± 3%) were demon-
strated with Click Chips using a much smaller quantity of TCO–anti- 
EpCAM (as low as 0.1 ng) per capture study than used with previous 
NanoVelcro Chips. In comparison, anti-EpCAM–mediated NanoVelcro 
Chips had a lower capture efficiency (46 ± 6%) and higher WBC 
(17,547 ± 2757) contamination when using the same quantity of 
anti-EpCAM capture agent (0.1-ng biotinylated anti-EpCAM per 
capture study). Moreover, 200 ng of anti-EpCAM was needed for 
anti-EpCAM–mediated NanoVelcro Chips to achieve equivalent CTC 
capture efficiency. The incidence of nonspecifically captured WBCs 
(1684 ± 613 WBCs) on the Tz-grafted SiNWS was markedly reduced, 
with approximately 10 times fewer WBCs than anti-EpCAM–mediated 
NanoVelcro Chips.
Using 0.1 ng of TCO–anti-EpCAM, we evaluated the effect of 
different flow rates (0.1 to 5 ml hour−1) on the CTC capture effi-
ciency of Click Chips. Our data suggest an optimum flow rate of 
1.0 ml hour−1, which results in an average capture efficiency of 94 ± 3% 
(Fig. 3D). The effects of both nanoscale topography (19) and surface 
chemistry were evaluated by comparing the CTC capture performance 
of (i) flat Si substrates without the Tz motif, (ii) Tz-grafted flat Si 
substrates, (iii) SiNWS without the Tz motif, and (iv) Tz-grafted 
SiNWS. All studies were performed using a flow rate of 1.0 ml hour−1. 
The Tz-grafted SiNWS outperformed the three control groups, 
suggesting that the synergistic integration of the covalent bio-
orthogonal ligation–mediated (22) CTC capture and the topographic 
interactions (19) between cells and nanostructured substrates 
(i.e., SiNWS) are critical for optimal CTC capture efficiency (Fig. 3E). 
We then compared the performance of Click Chips with Tz-grafted 
magnetic beads (fig. S5) using the same quantity of TCO–anti- 
EpCAM (0.1 ng per capture study). The magnetic bead–based 
sorting method exhibited a capture efficiency of 24 ± 1% with a high 
number (15,781 ± 4362) of nonspecifically trapped WBCs (Fig. 3F). 
These results demonstrate the superiority of Click Chip, which 
combines the advantages of bioorthogonal ligation, nanostructured 
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Fig. 2. Surface modification, characterization, and verification of Tz-grafted SiNWS. (A) Schematic summary of the stepwise functional group transformation devel-
oped for the preparation of Tz-grafted SiNWS. (B to D) X-ray photoelectron spectra of stepwise functionalized SiNWS: bare SiNWS (blue), SH-grafted SiNWS (orange), 
NH2-grafted SiNWS (green), and Tz-grafted SiNWS (red): (B) survey scans, (C) high-resolution XPS spectra in the energy range of the S 2p signals, and (D) high-resolution 
spectra in the energy range of the N 1s signals. (E) Scheme for verification of the successful preparation of Tz-grafted SiNWS via bioorthogonal ligation with Cy5-labeled 
TCO (2.6 mM) and disulfide cleavage by DTT (50 mM), respectively. Fluorescent images were captured through fluorescence microscopy (Nikon 90i, ex = 620/60) for 
(F) Tz-grafted SiNWS, (G) Cy5-grafted SiNWS, and (H) disulfide-cleaved SiNWS by DTT treatment. a.u., arbitrary units.
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Fig. 3. Validation and optimization of Click Chips using artificial NSCLC samples. (A) Schematic representation of the mechanisms for bioorthogonal ligation–
mediated capture and the disulfide cleavage–driven release of CTCs from Click Chips’ Tz-grafted SiNWS. (B) Schematic illustrating the conventional anti-EpCAM–mediated CTC 
capture process of NanoVelcro assays. (C) Comparison of CTC capture efficiency and specificity (i.e., nonspecifically captured WBCs) observed for Click Chips and NanoVelcro 
assays in the presence of 0.1, 20, and 200 ng of the respective anti-EpCAM capture agents (n = 3). (D) CTC capture efficiency of Click Chips was studied at flow rates of 0.1, 
0.2, 0.5, 1.0, 2.0, and 5.0 ml hour−1 (n = 3). (E) CTC capture efficiency observed for the four different control groups: flat Si substrates without the Tz motif, Tz-grafted flat Si 
substrates, SiNWS without the Tz motif, and Click Chips based on Tz-grafted SiNWS (n = 3). (F) Comparison of capture efficiencies and specificity of bioorthogonal 
ligation– mediated CTC capture on Click Chips and magnetic beads. (G) CTC release efficiency was measured for Click Chips at flow rates of 0.1, 0.2, 0.5, 1.0, 2.0, and 5.0 ml hour−1 (n = 3). 
(H) General applicability of Click Chips for CTC capture and release was validated using artificial samples containing different NSCLC cell lines, i.e., HCC78, H2228, HCC827, 
H1975, and WBCs (n = 3). (I) Dynamic ranges observed for CTC capture and release using Click Chips. Spiked CTC numbers range from 5 to 200 cells ml−1. (J) A double 
parameter scatter plot showing the HCC78/WBC cell distribution observed for CTC capture in a Click Chip. (K) A double parameter scatter plot showing the cell distribu-
tion observed for CTC release, following the above experiment (J).
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substrates, and herringbone-patterned PDMS together into a single 
device.
CTC release from Click Chips
The capability to release CTCs from the Tz-grafted SiNWS was 
studied using the optimized CTC capture conditions identified above 
(i.e., 0.1-ng TCO–anti-EpCAM, capture flow rate = 1.0 ml hour−1). 
The captured cells were released from the nanostructured surface 
by injecting 200 l of DTT (50 mM) into Click Chip devices. We 
examined the effect of flow rate (0.1 to 5 ml hour−1) on the CTC 
release efficiency and found that a rate of 1.0 ml hour−1 resulted in 
the most robust release and collection of cells (78 ± 4%) (Fig. 3G). 
Higher flow rates (>1.0 ml hour−1) resulted in damage to cells as the 
result of the higher shear forces and mechanical collision in the 
devices. Operating Click Chips at optimal conditions enables rapid CTC 
purification (capture and release) in 24 min. The general applicability 
of Click Chips was tested and validated using four artificial CTC 
samples composed of NSCLC cell lines, i.e., HCC78 (SLC34A2-ROS1), 
H2228 (EML4-ALK), HCC827 (EGFR exon19del E746-A750), or 
NCI-H1975 (EGFR L858R/T790M) mixed with populations of WBCs. 
In these studies, Click Chips can capture the NSCLC cells with 
average efficiencies between 88 and 94% and release the cells with 
comparable average efficiencies ranging between 75 and 81% (Fig. 3H). 
The dynamic range of Click Chips was evaluated using artificial CTC 
samples containing 5 to 200 HCC78 cells spiked into a population 
of WBCs (Fig. 3I). Click Chips exhibit consistent capture (y = 0.93x 
− 1.10, R2 = 0.999) and recovery rates (y = 0.75x − 1.84, R2 = 0.993) 
that are sufficient to detect CTCs in clinical samples. A representa-
tive study using an artificial CTC sample containing 200 HCC78 
cells (Fig. 3, J and K) demonstrated efficient CTC capture (186 of 200) 
and release (148 of 186) from Click Chips with minimal background 
(1682 WBC capture and 152 WBC release). More comprehensive experi-
mental data are compiled in table S1. These data suggest that the disulfide 
cleavage–driven release mechanism used here will further improve the 
purity of recovered CTC populations (ca. one order of magnitude 
reduction in WBC contamination), ensuring the collection of robust 
and reproducible samples for downstream molecular characterization.
Quantification of rearrangements using CTC-derived mRNA
We first demonstrated the feasibility and dynamic ranges of detect-
ing ALK/ROS1 rearrangements via RT-ddPCR with CTCs purified 
from artificial NSCLC cell line samples (figs. S6 and S7). Furthermore, 
we showed that disulfide cleavage–driven CTC release improved 
signal-to-noise ratio compared with on-chip cell lysis in detecting 
ROS1 rearrangement (fig. S8). Click Chip–mediated capture and 
release of CTCs were then validated using blood samples collected 
from patients with NSCLC (Fig. 4A). As shown in Table 1, blood 
was sampled from 12 late-stage patients with NSCLC who were 
treated with crizotinib and 6 healthy donors. Among the 12 pa-
tients with NSCLC, 7 patients harbored ALK rearrangements and 
5 patients harbored ROS1 rearrangements. Blood was drawn before 
and after initiation of crizotinib therapy for some patients. For 
each patient with NSCLC and each healthy donor, two 2.0-ml blood 
samples were separately subjected to (i) CTC capture in a Click 
Chip, followed by immunostaining and CTC enumeration (30), and 
(ii) CTC purification in a Click Chip, followed by RT-ddPCR analysis 
to quantify the copy numbers of rearranged ALK or ROS1 tran-
scripts. The CTC enumeration counts and copy numbers of 
rearranged ALK or ROS1 transcripts for individual samples are 
summarized in Table 1. The number of CTCs ranged from 0 to 36, 
and there are 2780 to 3196 WBCs in the Click Chips for each 
2-ml blood sample. We detected positive ALK or ROS1 rearrange-
ments in the CTCs collected from all 12 patients with NSCLC 
that were consistent with biopsies obtained at diagnosis. All the six 
healthy donors were negative for CTCs and rearranged ALK/ROS1 
transcripts.
Dynamic monitoring of CTCs and ALK/ROS1 rearrangements 
during treatment
In Fig. 4 (B to D), we track the treatment of patient A07 over time. 
Blood was collected serially before initiating crizotinib and then 30, 
60, 77, and 129 days after treatment. The dynamic changes are plotted 
for both the CTC count and the copy numbers of rearranged ALK 
transcripts detected in Fig. 4B. Computed tomography (CT) images of 
the patient showed that before treatment, the patient exhibited a 
heavy tumor burden in his left lung. Following the initiation of 
crizotinib, the patient’s tumor burden was reduced progressively 
over the course of 129 days (Fig. 4C). These radiographic observations 
are consistent with the reductions observed in both CTC count 
and ALK rearrangement transcripts detected. At the time of data 
cutoff, the patient’s treatment response with crizotinib was durable. 
Figure 4D shows a typical micrograph of CTCs from patient A07 
captured using the Click Chip system.
Serial blood draws were obtained before and after initiation of 
crizotinib therapy from a patient with NSCLC (R05) harboring ROS1 
rearrangement. The CTC count and copy numbers of rearranged ROS1 
transcripts are plotted in Fig. 4E. Corresponding CT images from 
the patient show lesions throughout the patient’s chest before starting 
crizotinib. The patient was found to have a partial response after 30 days 
of treatment but unfortunately relapsed after 75 days (Fig. 4F). The 
patient died of intractable tumor burden 78 days after entering the 
study. Dynamic changes in both the number of CTCs detected and 
the copy number of rearranged ROS1 transcripts were consistent 
with CT images and clinical outcomes. A typical micrograph of the CTCs 
captured by Click Chips from this patient with NSCLC is shown in 
Fig. 4G. These data serve as a powerful proof of concept for the capa-
bility to use CTCs collected via Click Chips to serve as a diagnostic 
tool for monitoring disease status in critically ill patients with cancer.
DISCUSSION
In this study, we have successfully developed and validated a new 
covalent chemistry–based CTC purification device (Click Chip) that 
enables efficient purification of pooled CTCs with well-preserved 
mRNA and low levels of WBC contamination, making it an excellent 
option for a CTC mRNA assay. We demonstrated the clinical utilities 
of Click Chips in NSCLC for (i) enumerating CTCs and (ii) quanti-
fying ALK/ROS1 rearrangements in pooled CTCs with well-preserved 
mRNA by coupling with RT-ddPCR. Our experimental data unveil 
that Click Chips exhibit markedly improved CTC capture efficiency 
and specificity compared with the controlled studies, paving the way 
for precise quantification of gene rearrangements in CTCs. The 
improved CTC capture efficiency and specificity observed for Click 
Chips are attributed to the synergistic integration of the covalent 
bioorthogonal ligation–mediated (22) CTC capture and nanostructured 
substrates (i.e., SiNWS) (19). The bioorthogonal ligation–mediated CTC 
capture is used to overcome the limitations associated with the con-
ventional antibody–mediated CTC capture methods. A pair of highly 
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reactive click chemistry motifs (i.e., TCO and TZ) were grafted onto 
CTCs and SiNWS via antibody conjugation and surface modification, 
respectively. When a blood sample is run through a Click Chip, the PDMS 
chaotic mixer facilitates physical contact between the TCO-grafted CTCs 
and the Tz-grafted SiNWS. These interactions trigger inverse electron- 
demand Diels-Alder reactions between TCO on the CTCs and Tz 
on the SiNWS, instantly and irreversibly immobilizing the CTCs. 
Previously, we demonstrated that the incorporation of nanostruc-
tured substrates (19, 25) into cell-affinity substrates resulted in 
enhanced cell capture affinities compared with those observed for 
nonstructured (i.e., flat) substrates. The results summarized in this 
study also suggest that incorporating SiNWS into the click chemistry– 
mediated CTC capture platform resulted in a markedly improved 
CTC capture efficiency (94 ± 3%) and specificity (with a 10-fold 
reduction in WBC contamination) using a much smaller quantity 
of TCO–anti-EpCAM (as low as 0.1 ng) per capture study. Our present 
experiential data suggest that the use of a single capture agent (i.e., 
TCO–anti-EpCAM) is sufficient to achieve the desired CTC cap-
ture performance in NSCLC. We envision that the proposed Click 
Chips can be synergistically coupled with a multimarker capture 
cocktail to capture and purify CTCs in the cancer types (e.g., HCC) 
that require multiple capture agents (31).
In addition to the improved CTC capture efficiency and specificity 
observed for Click Chips, incorporating a disulfide bond into the 
Fig. 4. Click Chips combined with RT-ddPCR analysis can be used to monitor dynamic changes in CTC count and CTC-derived ALK/ROS1 rearrangements in pa-
tients with NSCLC over the course of crizotinib (ALK/ROS1-TKI) treatments. (A) Schematic illustrating the general workflow developed for conducting CTC enumer-
ation and CTC-based ALK/ROS1 rearrangement quantification. (B) The dynamic changes (0 to 129 days) of CTC counts and rearranged ALK transcripts (per 2 ml of blood) 
observed for a patient with NSCLC harboring the EML4-ALK rearrangement (A07) before and after crizotinib treatment. (C) CT images of patient A07 taken at days 0, 77, 
and 129, after crizotinib treatment. (D) Representative fluorescent micrographs of CTCs (DAPI+/CK+/CD45–) captured from patient A07’s blood samples using Click Chips. 
(E) Dynamic change (0 to 75 days) of CTC counts and rearranged ROS1 transcripts (per 2 ml of blood) observed for a patient with NSCLC with the CD74-ROS1 rearrange-
ment (R05) before and after crizotinib treatment. (F) Chest CT scans of patient R05 taken at days 0, 30, and 75 after crizotinib treatment. (G) Representative fluorescent 
micrographs of the CTC populations obtained from patient R05.
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surface linker that tethers Tz motifs onto the SiNWS allows for 
disulfide cleavage–driven CTC release. Upon exposure to a mild 
disulfide cleavage agent (i.e., DTT) (26), the surface linkers anchoring 
the CTCs onto the SiNWS are cleaved, releasing the CTCs and leaving 
the nonspecifically trapped WBCs behind. We note that disulfide 
cleavage–driven CTC release confers a second layer of specificity, 
further improving CTC purification performance. Moreover, the 
well-preserved mRNA of purified pooled CTCs paves the way for 
seamless coupling with detection and quantification of oncologic 
gene rearrangements (i.e., ALK and ROS1). Compared with several 
reported release strategies such as dual-mode responsive gelatin (32), 
ligand competition (9), DNA displacement (33), aptamer/enzyme 
digestion (34), and light exposure (35), our method could retrieve 
CTCs under milder conditions with enhanced purity and reduced 
Table 1. Clinical characteristics of patients with NSCLC (adenocarcinoma) and healthy donors (HD) enrolled in our study. N/A, not applicable. 
Patient 
number Gender Age (years)
Smoking 
history 
(years)
Tumor grade Clinical stage CTC counts*
ALK/
ROS1 
status 
(tissue)
ALK/
ROS1 
status 
(CTCs)
Copy numbers of 
ALK/ROS1 
rearrangements 
in CTCs*
A01 Male 53 None 3 IV 18 EML4-ALK EML4-ALK 333
A02 Male 38 None 3 IV 15 EML4-ALK EML4-ALK 603
A03 Male 65 None 3 IV 32 EML4-ALK EML4-ALK 198
A04 Female 65 None 3 IV 27 EML4-ALK EML4-ALK 1728
A05 Male 53 None 3 IV 16 EML4-ALK EML4-ALK 252
A06 Male 58 None 3 IV 26 EML4-ALK EML4-ALK 207
A07-1 Male 39 None 2 IV 15 EML4-ALK EML4-ALK 108
A07-2 Male 39 None 2 IV 11 EML4-ALK EML4-ALK 81
A07-3 Male 39 None 2 IV 9 EML4-ALK EML4-ALK 54
A07-4 Male 39 None 2 IV 0 EML4-ALK EML4-ALK 0
A07-5 Male 39 None 2 IV 0 EML4-ALK EML4-ALK 0
R01 Female 62 None 3 IIIB 28 CD74-ROS1
CD74-
ROS1 504
R02 Male 41 None 2 IIIB 22 CD74-ROS1
CD74-
ROS1 594
R03 Male 61 35 2 IV 17 CD74-ROS1
CD74-
ROS1 684
R04 Male 34 None 3 IV 27 CD74-ROS1
CD74-
ROS1 963
R05-1 Male 32 None 3 IV 28 CD74-ROS1
CD74-
ROS1 1773
R05-2 Male 32 None 3 IV 6 CD74-ROS1
CD74-
ROS1 162
R05-3 Male 32 None 3 IV 36 CD74-ROS1
CD74-
ROS1 2061
HD01 Male 30 None N/A N/A 0 N/A N/A 0
HD02 Male 26 None N/A N/A 0 N/A N/A 0
HD03 Male 29 None N/A N/A 0 N/A N/A 0
HD04 Male 46 None N/A N/A 0 N/A N/A 0
HD05 Female 36 None N/A N/A 0 N/A N/A 0
HD06 Male 32 None N/A N/A 0 N/A N/A 0
*Per 2 ml of blood.
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processing time, thereby providing better preserved CTC-derived 
mRNA. Besides, our experimental data have demonstrated the 
advantages of post-release lysis of purified CTCs over on-chip lysis 
in the ROS1 rearrangement detection using artificial HCC78 CTC 
samples. We attribute the higher copy number of ROS1 rearrange-
ment detected using the mRNA extracted from the post-release 
lysis to (i) the high yield of CTC capture/release, (ii) the short CTC 
purification time (24 min), (iii) the mild processing conditions, 
and (iv) the protection of CTC membranes for their RNA contents. 
In comparison, mRNA exposed by on-chip lysis of CTCs is contam-
inated by mRNA from a relatively large number of WBCs, which 
leads to the targetable gene rearrangement being buried in irrelevant 
background. Moreover, it is difficult to flush CTC-RNA from the 
densely arranged Si nanowires, further increasing the value of the 
CTC releasing process in our platform.
In patients with NSCLC, the presence of ALK/ROS1 rearrange-
ments defines a distinct molecular subgroup that may benefit from 
the treatment of ALK/ROS1-TKIs (i.e., crizotinib) (36). Despite the 
effectiveness of crizotinib in ALK/ROS1-positive NSCLC, most pa-
tients eventually develop acquired resistance to crizotinib, typically 
within 1 year (37, 38). Therefore, quantifying ALK/ROS1 rearrangement 
by RT-ddPCR in CTCs may serve as a complementary method pro-
viding early prediction of clinical treatment responses, offering an 
invaluable glimpse into the longitudinal evolution of ALK/ROS1 
rearranged NSCLC during ALK/ROS1-TKI treatment. Although 
fluorescence in situ hybridization (FISH) tests have been used to 
detect gene rearrangements in CTCs, adopting these CTC-based 
FISH tests in clinical settings is challenging (39). The rare FISH 
events need to be visually identified with high-resolution fluores-
cent microscopy after confirming the CTCs’ positions via immuno-
fluorescence staining. These laborious procedures would introduce 
significant burden to laboratory personnel and pathologists. These 
CTC-based FISH tests are unable to provide quantitative readouts 
or to identify the fusion gene partners (13). We demonstrate that 
Click Chips can be applied for both CTC enumeration and purification 
using blood samples collected from patients with NSCLC. The purified 
CTCs can then be quantified in terms of ALK/ROS1 rearrangements 
by RT-ddPCR with single-molecule precision. We applied this ca-
pability to correlate dynamic changes in both CTC count and in the 
quantification of CTC-derived ALK/ROS1 rearrangements to out-
comes from radiographic imaging, the clinical gold standard for 
evaluating responses of solid tumors. Compared with CTC counts, 
quantification of CTC-derived ALK/ROS1 rearrangements yields a 
broader dynamic range, enabling more precise monitoring of treatment 
response and/or disease progression in patients with NSCLC. These 
results can empower oncologists to make more informed and precise 
therapeutic decisions as they direct the care of their patients.
MATERIALS AND METHODS
Fabrication of Tz-grafted SiNWS
Vertically aligned SiNWS were prepared via a combination of photo-
lithographic patterning and silver (Ag) nanoparticle–templated wet 
etching (27) according to the procedures described in our previous 
publication (25). Briefly, a thin-film photoresist (AZ 5214, AZ Electronic 
Materials USA Corp.) was spin-coated onto a (100) p-type silicon 
(Si) wafer (Silicon Quest International) with resistivity approximately 
10 to 20 ohm·cm. After being exposed to ultraviolet (UV) light, the 
Si wafer was immersed into the etching solution containing hydro-
fluoric acid (4.6 M; Sigma-Aldrich), silver nitrate (AgNO3, 0.2 M; 
Sigma-Aldrich), and deionized water. After that, the Si wafer was 
immersed in boiling aqua regia [hydrochloric acid (HCl)/nitric acid 
(HNO3), 3:1 (v/v); Sigma-Aldrich] for 15 min to remove the silver 
film. The resulting Si nanowires had a length of approximately 10 m. 
The SiNWS were rinsed with acetone (≥99.5%; Sigma-Aldrich) 
and then ethanol (anhydrous; Sigma-Aldrich) several times to remove 
the patterned photoresist. A three-step chemical modification was 
developed to introduce a disulfide linker coupled to the Tz motif 
onto the chip surfaces. (i) For surface silanization, the SiNWS were 
placed into a Teflon frame in a glass beaker and incubated with a 
piranha solution [sulfuric acid (H2SO4)/hydrogen peroxide (H2O2), 
2:1 (v/v); Sigma-Aldrich] for 1 hour. After rinsing successively with 
deionized water and ethanol three times, the SiNWS were then dried 
with nitrogen gas and then sealed in a vacuum desiccator and 
exposed to silane vapor coming from MPS (211.4 mg, 200 l; Sigma- 
Aldrich) for 45 min to introduce thiol groups onto the SiNWS. (ii) 
Freshly prepared HS-SiNWS were incubated with OPSS-PEG-NH2 
(0.30 mg, 3.8 mM; Nanocs Inc.) in dimethyl sulfoxide (200 l) solution 
for 2 hours to incorporate disulfide linkers with terminal amine groups. 
The obtained amine-terminated silicon nanowire substrates (H2N-SiNWS) 
were rinsed with ethanol three times. (iii) To graft Tz motifs onto 
SiNWS, the H2N-SiNWS were reacted with Tz-sulfo-NHS ester (0.32 mg, 
3.8 mM; Click Chemistry Tools Bioconjugate Technology Company) 
in phosphate-buffered saline (PBS) buffer (200 l) for 1 hour. The 
functionalized Tz-grafted SiNWS were rinsed with PBS three times 
before use for CTC capture and release experiments.
Preparation of microfluidic chaotic mixer components
Microfluidic chaotic mixer substrates were fabricated from a photo-
lithographically prepared master wafer prepared by inductively coupled 
plasma-reactive ion etching (25, 40). The master wafer was fabricated 
by spin-coating a 75-m-thick layer of negative photoresist (MicroChem 
Corp.) onto a 76-mm silicon wafer. The silicon wafer was then ex-
posed to UV light through a photomask composed of a serpentine 
rectangular microfluidic channel (22-cm length and 2.0-mm width). 
Next, a layer of a second negative photoresist was spin-coated onto 
the wafer with a thickness of 40 m. A second photomask composed 
of herringbone ridges was aligned between the previously exposed 
pattern and the pattern to be imprinted using a Mask Aligner (Karl 
Suss America Inc.). The tops of the resulting microchannels have 
ridges that were used to promote chaotic mixing within the micro-
fluidic network. Before replica molding, the Si master was pretreated 
by exposure to trimethylchlorosilane vapor for 1 min. The silane- 
treated master was transferred to a petri dish. The petri dish was 
filled with the well-mixed PDMS precursor (RTV 615 A and B in a 
10:1 ratio; GE Silicones), degassed, and then incubated in an oven at 
80°C for 48 hours to make a 5-mm-thick chip. The PDMS microfluidic 
chaotic mixer was peeled off from the silicon master wafer/mold, 
and two through-holes were punched at the ends of the channel for 
insertion of tubing.
Assembling Click Chips in chip holders
A chip holder was custom-designed to establish a secure seal 
between the Tz-grafted SiNWS and the PDMS component. Multiple 
alignment markers were designed on the substrates to enable rapid 
assembly of Click Chip devices (within 1 min). A fully automated 
digital fluidic handling system composed of two PSD4 syringe pumps 
(Hamilton Robotics), rotary valves, and a controller program with 
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graphical user interface was used to control the loading of reagents and 
test samples as well as automatically coordinate CTC capture and release.
X-ray photoelectron spectroscopic characterization
The analysis was carried out in a PHI 5000 VersaProbe system (ULVAC- 
PHI; Chigasaki) using a microfocus (100 m, 25 W) Al K x-ray source 
with photoelectrons collected from a takeoff angle of 45°. Function-
alized SiNWS were vacuum-dried overnight before being transferred 
into the system for analysis. During spectral acquisition, a dual-beam 
charge neutralizer (7-V Ar+ and 1-V flooding electron beam) was 
used to compensate for any charging effects. Survey spectra over 
a binding energy range of 0 to 1000 were measured for SiNWS, 
HS-SiNWS, H2N-SiNWS, and Tz-grafted SiNWS. High-resolution 
XPS spectra of S 2p, N 1s, C 1s, and O 1s were also collected. The 
C─C peak corresponding to adventitious carbon (C 1s = 284.6 eV) 
was used to calibrate binding energies.
Fluorescence characterization of Tz-grafted SiNWS
To demonstrate the feasibility and specificity of bioorthogonal liga-
tion between Tz and TCO motifs on Tz-grafted SiNWS, Cy5-labeled 
TCO reagent (2.6 mM, Click Chemistry Tools Bioconjugate Technology 
Company) in PBS (200 l) was used to treat Tz-grafted SiNWS as 
well as H2N-SiNWS (as a control) for 30 min. Unbound Cy5-labeled 
TCO was rinsed off with deionized water five times before charac-
terization. Fluorescence images were collected with a fluorescence 
microscope (Nikon 90i; ex = 590 to 650 nm, exposure time = 500 ms). 
To investigate disulfide cleavage after bioorthogonal ligation, the 
Cy5-grafted SiNWS were treated with DTT (3.8 mM; Sigma-Aldrich) 
in PBS (200 l) for 0, 15, 30, 45, and 60 min and DTT (50 mM) in 
PBS (200 l) for 0, 3, 6, 9, 12, 15, 20, 30, 45, and 60 min, respectively. 
After being rinsed by deionized water five times, the fluorescence 
images were collected using a fluorescence microscope. Average 
fluorescence intensity of Cy5 on substrates was calculated using the 
NIS-Elements AR 4.20 software package.
Preparation of TCO–anti-EpCAM conjugate
TCO–anti-EpCAM conjugate was prepared by incubating TCO-
PEG4-NHS ester (0.5 mM; Click Chemistry Tools Bioconjugate 
Technology Company) with human EpCAM/TROP-1 antibody 
[goat immunoglobulin G (IgG), 0.5 g l−1; R&D Systems Inc.] in 
PBS at room temperature for 30 min. The TCO–anti-EpCAM con-
jugate was diluted to 0.005 g l−1 and stored at −20°C.
NSCLC cell lines
Four NSCLC cell lines including HCC78, H2228, HCC827, and 
H1985 were purchased from American Type Culture Collection 
and cultured using RPMI 1640 1640 growth medium with 10% fetal 
bovine serum, 1% GlutaMAX-I, and penicillin-streptomycin (100 U ml−1) 
(Thermo Fisher Scientific) in a humidified incubator with 5% CO2.
Artificial CTC sample studies
To enable convenient cell imaging and counting, cultured EpCAM- 
positive NSCLC cells (1 × 106 ml−1) were prestained with a Vybrant 
DiO green fluorescent dye (Invitrogen) in serum-free culture medium 
at 37°C for 1 hour. EpCAM-negative WBCs were isolated from 
blood samples of the healthy donors with approval from the University 
of California, Los Angeles Institutional Review Board (no. 00000173) 
and then prestained with a Vybrant DiD red fluorescent dye (Invitrogen). 
Excess cell-labeling dye was removed by centrifuging the labeled 
suspension at 1500 rpm for 5 min and washed with PBS twice. Typical 
artificial CTC samples were prepared by spiking 200 prestained NSCLC 
cells into the prestained WBCs (5 × 106 cells ml−1) in 200 l of 
RPMI 1640. The artificial CTC sample was incubated with TCO–
anti- EpCAM (0.1 ng) in RPMI 1640 (200 l) at room temperature 
for 30 min and then centrifuged at 300g for 10 min to remove the 
excess TCO–anti-EpCAM and nonreactive TCO-PEG4-NHS ester. 
The resulting samples containing TCO-grafted CTCs were then puri-
fied using Click Chips. For CTC enumeration, the cells captured on 
Tz-grafted SiNWS were stained with DAPI and imaged under a fluo-
rescence microscope (Nikon 90i, W1, 325 to 375 nm; W2, 465 to 495 nm; 
W3, 590 to 650 nm).
CTC capture and release from Click Chips
For CTC capture, PBS (200 l) was first introduced into a Click 
Chip via a digital fluidic handler at a flow rate of 1 ml hour−1 to 
confirm that an appropriate seal was made between the patterned 
PDMS chaotic mixer and the Tz-grafted SiNWS. The TCO-grafted 
artificial CTC samples and peripheral blood mononuclear cell (PBMC) 
samples (200 l) collected from patients with NSCLC were infused 
into Click Chip microfluidic devices at the optimum flow rate of 1 ml 
hour−1. For CTC enumeration, the CTCs captured in Click Chip 
were fixed with 2.0% formaldehyde (Electron Microscopy Sciences) 
in PBS (200 l). CTCs captured on the chips were enumerated. To 
release CTCs, 200 l of DTT (50 mM) was injected into the Click 
Chip system at a flow rate of 1 ml hour−1, and then 100 l of PBS was 
injected at a flow rate of 1 ml hour−1 to collect the released CTCs. 
The released CTCs were collected into either a 96-well plate for 
fluorescence imaging or 1.5-ml ribonuclease (RNase)–free Eppendorf 
tubes for subsequent molecular analysis using RT-ddPCR.
Patients with NSCLC and treatments
We consecutively enrolled 12 patients with treatment-naïve advanced 
NSCLC (stages III and IV) from October 2016 to June 2017, including 
7 patients who harbored the ALK rearrangement (13, 14) and 5 patients 
with known ROS1 rearrangement. Patients who had other uncon-
trolled malignant tumors, uncontrolled infection or Mycobacterium 
tuberculosis, or severe mental disease were excluded. Physicians and 
patients made treatment decisions together, and all the 12 enrolled 
patients received crizotinib as a first-line therapy. All the enrolled 
patients underwent follow-up imaging examinations every 2 to 3 months, 
and their clinical responses were evaluated according to the Response 
Evaluation Criteria in Solid Tumors (RECIST 1.1). This study was 
approved by the Ethics Committee of Guangdong Provincial Hospital 
of Traditional Chinese Medicine, and all patients provided written 
informed consent for this study.
Pathological examination of NSCLC tissue sections
Pathological examination including hematoxylin and eosin (H&E) 
staining, immunohistochemistry (IHC), and ALK/ROS1 rearrange-
ment analysis of the biopsies obtained from the 12 enrolled patients 
was performed independently by experienced pathologists from 
Guangdong Provincial Hospital of Traditional Chinese Medicine. 
All the tumor samples were fixed in 10% neutral formalin for 24 to 
48 hours and embedded in paraffin. The H&E staining was performed 
following Clinical Laboratory Improvement Amendments–compliant 
methods and equipment. Serial 4-m-thick tissue sections from 
formalin-fixed paraffin-embedded (FFPE) blocks were cut and mounted 
on poly- l-lysine–coated glass slides. Standard IHC staining on 
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4-m-thick tissue sections was performed on Ventana BenchMark 
ULTRA Slide Stainer according to a protocol optimized for each 
antibody as determined by conventional IHC. The IHC analyses for 
P63, CK5/6, CK7, thyroid transcription factor-1 (TTF-1), Napsin A, CD56, 
synaptophysin (SYN), and chromogranin A (CgA) were performed to 
differentiate between NSCLC (adenocarcinoma and squamous cell 
carcinoma) and small cell lung cancer in the poorly differentiated cases. 
Positive CK7, Napsin A, and/or TTF-1 staining combined with negative 
P63, CK5/6, CD56, SYN, and CgA staining confirmed the diagnosis 
of lung adenocarcinoma enrolled in this study.
ALK/ROS1 rearrangement analysis of NSCLC tissue
ALK/ROS1 rearrangement analysis of tissue was performed according 
to the standard protocols in the Molecular Pathology Department 
of Guangdong Provincial Hospital of Traditional Chinese Medicine.
The ALK/ROS1 rearrangements were detected by RT real-time 
PCR using a fusion gene detection kit (Amoy, Xiamen, China, China 
Food and Drug Administration–approved), which covers 26 ALK gene 
rearrangement subtypes and 14 ROS1 gene rearrangement subtypes. 
Total RNA was extracted from FFPE tissue sections using Qiagen 
(Dusseldorf, Germany) RNeasy FFPE kit. Complementary DNA (cDNA) 
was synthesized under the following conditions: 42°C, 1 hour; 95°C, 
5 min. The conditions used for real-time PCR were as follows: an 
initial denaturation at 95°C for 5 min, followed by 15 cycles of 95°C 
for 25 s, 64°C for 20 s, and 72°C for 20 s and 31 cycles of 93°C for 25 s, 
60°C for 35 s, and 72°C for 20 s.
Collection and treatment of blood samples from  
patients with NSCLC
Peripheral venous blood samples were collected serially before and 
after initiation of crizotinib therapy with the written informed con-
sent of these patients. Each 5.0-ml blood sample was collected in 
a BD Vacutainer glass tube (BD Medical, Thermo Fisher Scientific 
catalog no. 02-684-26) with acid citrate dextrose. For each sample of 
the patient with NSCLC, two 2.0-ml vials of blood were separately centri-
fuged to collect PBMCs. The isolated PBMCs were then incubated 
with TCO–anti-EpCAM (0.1 ng) in PBS (200 l) at room temperature 
for 30 min before being loaded into Click Chip devices. One 2.0-ml 
blood sample was used for CTC capture and enumeration. In parallel, 
the other 2.0-ml blood sample was used for CTC release and ALK/
ROS1 rearrangement quantification by RT-ddPCR.
Immunofluorescence characterization of CTCs captured 
from blood samples
A three-color immunocytochemistry analysis (30) was adopted for 
immunofluorescence characterization of CTCs captured from 
blood samples collected from patients with NSCLC. The cells captured 
on Tz-grafted SiNWS were incubated with 0.05% Triton X-100 [in 
PBS (200 l)] for 10 min. The captured cells were incubated overnight 
with a mixture of primary antibodies including Pan-CK antibody 
[rabbit, polyclonal, 1:100 (v/v); Dako] and anti-CD45 antibody [F10-89-4] 
[mouse, monoclonal, 1:400 (v/v); Abcam] in a PBS solution (200 l) 
containing 2% normal donkey serum (Jackson ImmunoResearch) 
at 4°C. After washing with PBS three times, the captured cells 
were further incubated at room temperature for 1 hour with a mix-
ture of secondary antibodies including donkey anti-rabbit IgG (H+L) 
[Alexa Fluor 488, 1:500 (v/v); Invitrogen] and donkey anti-mouse IgG 
(H+L) [Alexa Fluor 647, 1:500 (v/v); Invitrogen] in a PBS solution 
(200 l) containing 2% donkey serum. After washing with PBS three 
times, the cells were treated with ProLong Gold Antifade Mountant 
with DAPI (Invitrogen). The substrates were then imaged with a 
fluorescence microscope (Nikon 90i). The captured CTCs were 
differentiated from background WBCs according to their unique 
staining pattern (CK+/CD45−/DAPI+) and intact nuclear morphology 
(WBCs were stained CK−/CD45+/DAPI+).
RNA extraction and RT-ddPCR detection of ALK/ROS1 
rearrangement in CTCs
The CTCs released from Click Chips were collected in a 1.5-ml 
RNase-free Eppendorf tube and lysed by TRI Reagent [1:3, (v/v), 
Zymo Research Corp.]. The collected RNA was purified using a 
Direct-zol RNA MicroPrep Kit (Zymo Research Corp.) according to the 
manufacturer’s protocol. The purified RNA was reverse-transcribed 
to cDNA using a Thermo Scientific Maxima H Minus Reverse 
Transcriptase Kit according to the manufacturer’s instructions. 
Samples of cDNA were detected with a PrimePCR ddPCR Expert 
Design Assay Kit from Bio-Rad that covers 26 ALK gene rearrange-
ment subtypes and 14 ROS1 gene rearrangement subtypes. Data 
were analyzed using the QuantaSoft software package to calculate 
the corresponding copy numbers of ALK or ROS1 rearrangements 
detected from individual samples.
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